StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
318160.KQ$5250.00-3.67%
Fair $5250.00+0.0%

318160.KQ

Cell Bio Human Tech Co.,Ltd

Consumer Defensive / Household & Personal ProductsKOSDAQ

$5250.00

-200.00 (-3.67%)

Fairly Valued+0.0%Fair Value $5250.00Fund rank 25/100 · Data gapFallback financials|
SA 53/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 17%

FCF escenarios

weak_data · normalized FCF $626.6M · quality 40.0/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 14/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

53/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 318160.KQLocal privado en este navegador · Cell Bio Human Tech Co.,Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$42.8B

P/E

5.0x

↓

EV/EBITDA

4.1x

↓

ROE

15.4%

↑

Gross Margin

36.9%

↑

Debt/Equity

0.36

↓
52-Week Range$5250
$5200$11510

TradingView lightweight chart

318160.KQ price, volumen y niveles de valoración

Último $5,250Periodo -48.0%
Fair value: $5,250

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+22.8%

FCF CAGR

—

FCF margin

-10.4%

FCF / Net income

-0.61x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $51.07B · net income $8.72B · FCF $-5.32B

2022-FY → 2025-FY

Gross margin

36.9%+9.2% pts

Operating margin

18.2%+5.4% pts

Net margin

17.1%+6.6% pts

FCF margin

-10.4%-10.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$51.07B$51.07B$28.42B$27.32B$27.54B
Net Income$8.72B$8.72B$4.38B$-1.86B$2.89B
EBITDA$11.74B$11.74B$7.51B$1.48B$5.86B
EPS1059.001059.00491.00-220.00413.00
Gross Margin36.9%36.9%31.8%28.3%27.7%
Operating Margin18.2%18.2%14.2%11.5%12.8%
Net Margin17.1%17.1%15.4%-6.8%10.5%
Balance Sheet
Debt/Equity0.360.360.090.130.16
Current Ratio2.432.43———
Cash Flow
Free Cash Flow$-5.32B$-5.32B$7.24B$626.6M$62.9M
Returns
ROE15.4%15.4%9.4%-4.2%9.0%
Valuation
P/E4.964.966.57——
EV/EBITDA4.074.073.9625.61—
P/B0.760.760.620.81—
Growth & Yield
Revenue Growth79.7%79.7%4.0%-0.8%—
EPS Growth115.7%115.7%323.2%-153.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-23.9%

fácil

EPS terminal req.

$465.85

Spread vs growth

139.6%

5Y implied EPS CAGR

-11.8%

fácil

EPS terminal req.

$563.68

Spread vs growth

127.5%

10Y implied EPS CAGR

-1.5%

fácil

EPS terminal req.

$907.81

Spread vs growth

117.2%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -9.2%

Total return

-9.2%

Start / end P/E

11.8x → 5.0x

EPS bridge

491.00 → 1059.00

Residual

-67.0%

EPS growth+115.7%
Multiple rerating-57.9%
Dividend+0.0%
Residual / FX / buybacks / cross-term-67.0%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.